Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2012

View Archived Issues

PaxVax presents phase I results on single-dose live oral cholera vaccine

A novel bispecific antibody shows tumor specificity in vivo

Lipoquin provides protection in murine model of pneumonic plague

Researchers at Bayer synthesize new cyclin-dependent kinase inhibitors

Oxford BioMedica provides update on ocular gene therapy candidates

FDA recommends continuation of Emmaus Medical's phase III sickle cell disease study

Astellas files sNDA for Tarceva in specific NSCLC subtype

European Commission approves Bayer's oral anticoagulant Xarelto for new indication

LEO Pharma's Picato gel receives European approval for actinic keratosis

Neovacs discloses final results from phase II TNF-alpha kinoid study

RNAi modifications: Progression from the bench to the clinic

Antisense morpholinos devised to treat spinal muscular atrophy

Dicerna's Dicer Substrate siRNA in lipid nanoparticles targets beta-catenin

Bayer Intellectual Property patents novel GCS activators

New C. difficile vaccines patented by Pfizer

GlaxoSmithKline synthesizes new bromodomain inhibitors

Ancora Pharmaceuticals presents new vaccines for Staphylococcus infection

New bispecific antibodies for cancer prepared by Genmab

Regen BioPharma begins preclinical study of HemaXellerate cell therapy

Atox Bio releases encouraging phase IIa topline results for AB-103

TMZ-POH has cytotoxic effects in temozolomide-resistant glioma cell lines

Preclinical study of H5N1 VLP vaccine shows cross-protection effects

European Commission approves Eliquis to prevent stroke in nonvalvular atrial fibrillation

Supernus' antiepileptic drug granted 3 years of market exclusivity in U.S.

XBiotech reports on interim analysis from phase II trial of monoclonal antibody

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...